Although BRAF mutations are less common in CCA than in melanoma or thyroid cancer, they activate the MAPK/ERK and MEK signaling pathways, promoting tumor proliferation and survival, and thus represent promising therapeutic targets. The gene discussed is BRAF; the disease is cholangiocarcinoma.